Recordati's silodosin approved in EU for BPH
This article was originally published in Scrip
Executive Summary
Recordati's Urorec (silodosin) has been approved in the EU for the treatment of benign prostatic hyperplasia (BPH). The approval decision follows the CHMP's recommendation to approve the drug in November (scripnews.com, November 20th, 2009).